Abdominal Aortic Aneurysm
Conditions
Interventions
Colchicine group:Colchicine treatment
Plocebo group:Plocebo treatment
Sponsors
Guangdong Provincial People's Hospital, Guangdong Institute of Cardiovascular Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.The diameter of the subrenal abdominal aneurysm by CTA or abdominal aorta ultrasound: 30-50mm; 2.Without clinical indication of endovascular repair or surgical operation for abdominal aneurysm; 3.Sign informed consent and be able and willing to comply with the research program.
Exclusion criteria
Exclusion criteria: 1.Colchicine is currently in use; 2.Previous endovascular repair or surgery for abdominal aortic aneurysm; 3.Allergic to colchicine; 4.Severe hepatic and renal insufficiency; 5.Inflammatory bowel disease or chronic diarrhea; 6.Glucocorticoids are currently being used or planned for long-term use; 7.Patients with malignant tumor and autoimmune disease; 8.Now he has participated in other clinical studies of interventional therapy or drug therapy, which may interfere with the research results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of maximum diameter of abdominal aortic aneurysm by angiography;Abdominal aortic ultrasonography changes the maximum diameter of abdominal aortic aneurysm; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of maximum volume of abdominal aortic aneurysm by angiography;The composite end point of abdominal aortic aneurysm rupture, requiring surgical or interventional treatment;Composite endpoint of myocardial infarction, ischemia driven coronary intervention, cardiac death and ischemic stroke;All cause death, abdominal aortic aneurysm related death and cardiovascular related death;Changes of biomarkers related to abdominal aortic aneurysm; | — |
Countries
China
Contacts
Public ContactLuo Jianfang
Guangdong Provincial People's Hospital, Guangdong Institute of Cardiovascular Diseases
Outcome results
None listed